transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression.

Författare och institution:
F Hieronymus (Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi); Johan Fredrik Emilsson (Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi); Staffan Nilsson (Institutionen för matematiska vetenskaper, matematisk statistik, Chalmers/GU); Elias Eriksson (Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi)
Publicerad i:
Molecular psychiatry, 21 ( 4 ) s. 523-30
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
The recent questioning of the antidepressant effect of selective serotonin reuptake inhibitors (SSRIs) is partly based on the observation that approximately half of company-sponsored trials have failed to reveal a significant difference between active drug and placebo. Most of these have applied the Hamilton depression rating scale to assess symptom severity, the sum score for its 17 items (HDRS-17-sum) serving as effect parameter. In this study, we examined whether the negative outcomes of many SSRI trials may be partly caused by the use of this frequently questioned measure of response. We undertook patient-level post-hoc analyses of 18 industry-sponsored placebo-controlled trials regarding paroxetine, citalopram, sertraline or fluoxetine, and including in total 6669 adults with major depression, the aim being to assess what the outcome would have been if the single item depressed mood (rated 0-4) had been used as a measure of efficacy. In total, 32 drug-placebo comparisons were reassessed. While 18 out of 32 comparisons (56%) failed to separate active drug from placebo at week 6 with respect to reduction in HDRS-17-sum, only 3 out of 32 comparisons (9%) were negative when depressed mood was used as an effect parameter (P<0.001). The observation that 29 out of 32 comparisons detected an antidepressant signal from the tested SSRI suggests the effect of these drugs to be more consistent across trials than previously assumed. Further, the frequent use of the HDRS-17-sum as an effect parameter may have distorted the current view on the usefulness of SSRIs and hampered the development of novel antidepressants.Molecular Psychiatry advance online publication, 28 April 2015; doi:10.1038/mp.2015.53.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Medicinska grundvetenskaper ->
Farmakologi och toxikologi ->
Selective serotonin, depressed mood, major depression
Postens nummer:
Posten skapad:
2015-12-16 08:47
Posten ändrad:
2016-04-29 14:49

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007